Physician profile
Michael Shea
NPI 1124146469
$510.66
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.77 · 2020: $14.85 · 2021: $365 · 2022: $41.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $199.99 | 2021 | |
| Dompe US, INC. | $120.78 | 2021 | |
| Coopervision INC. | $88.77 | 2019 | |
| Kala Pharmaceuticals, INC. | $44.67 | 2021 | |
| Bausch & Lomb Americas INC. | $22.10 | 2022 | |
| Biotissue Holdings INC. | $19.50 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.85 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.